365 related articles for article (PubMed ID: 19949928)
21. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
[TBL] [Abstract][Full Text] [Related]
22. Effect of oxygen on multidrug resistance in the first trimester human placenta.
Lye P; Bloise E; Dunk C; Javam M; Gibb W; Lye SJ; Matthews SG
Placenta; 2013 Sep; 34(9):817-23. PubMed ID: 23790363
[TBL] [Abstract][Full Text] [Related]
23. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters.
Choudhuri S; Klaassen CD
Int J Toxicol; 2006; 25(4):231-59. PubMed ID: 16815813
[TBL] [Abstract][Full Text] [Related]
24. Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy.
Hahnova-Cygalova L; Ceckova M; Staud F
Drug Metab Rev; 2011 Feb; 43(1):53-68. PubMed ID: 20854129
[TBL] [Abstract][Full Text] [Related]
25. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
26. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
27. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
28. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
29. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.
Natarajan K; Xie Y; Baer MR; Ross DD
Biochem Pharmacol; 2012 Apr; 83(8):1084-103. PubMed ID: 22248732
[TBL] [Abstract][Full Text] [Related]
30. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
[TBL] [Abstract][Full Text] [Related]
31. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
Shepard RL; Cao J; Starling JJ; Dantzig AH
Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064
[TBL] [Abstract][Full Text] [Related]
32. The multidrug resistance protein breast cancer resistance protein (BCRP) protects adipose-derived stem cells against ischemic damage.
van Dijk A; Naaijkens BA; Jurgens WJ; Oerlemans R; Scheffer GL; Kassies J; Aznou J; Brouwer M; van Rossum AC; Schuurhuis GJ; van Milligen FJ; Niessen HW
Cell Biol Toxicol; 2012 Oct; 28(5):303-15. PubMed ID: 22801743
[TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
34. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro.
Storch CH; Ehehalt R; Haefeli WE; Weiss J
J Pharmacol Exp Ther; 2007 Oct; 323(1):257-64. PubMed ID: 17652262
[TBL] [Abstract][Full Text] [Related]
35. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).
González-Sarrías A; Miguel V; Merino G; Lucas R; Morales JC; Tomás-Barberán F; Alvarez AI; Espín JC
J Agric Food Chem; 2013 May; 61(18):4352-9. PubMed ID: 23586460
[TBL] [Abstract][Full Text] [Related]
36. Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells.
Nathwani SM; Butler S; Fayne D; McGovern NN; Sarkadi B; Meegan MJ; Lloyd DG; Campiani G; Lawler M; Williams DC; Zisterer DM
Cancer Chemother Pharmacol; 2010 Aug; 66(3):585-96. PubMed ID: 20020128
[TBL] [Abstract][Full Text] [Related]
37. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
[TBL] [Abstract][Full Text] [Related]
39. Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.
Mao Q; Unadkat JD
AAPS J; 2015 Jan; 17(1):65-82. PubMed ID: 25236865
[TBL] [Abstract][Full Text] [Related]
40. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
